BCLI

BrainStorm Cell

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 0

stock price surged significantly

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About BCLI

Brainstorm Cell Therapeutics Inc.

A leading developer of cellular therapies for neurodegenerative diseases

Industry

Biological Technology

Established Date

09/22/2000

Listing Date

09/30/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.brainstorm-cell.com

Security Type

Common stock

Office address

1325 Avenue of Americas, 28th Floor, New York, NY 10019

Business

Introduction

BrainStorm Cell Therapeutics Inc., was incorporated under the laws of Washington State on September 22, 2000 and re-incorporated in Delaware on November 15, 2006. The Company is a leading biotechnology company dedicated to the development and commercialization of best-in-class autologous cell therapies for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis; progressive multiple sclerosis (" PMS "); Alzheimer's disease (" AD "); and neurodegenerative diseases. The Company's proprietary cell therapy platform, NurOwn, utilizes cell culture methods to induce autologous bone marrow mesenchymal stem cells (" MSCs ") to secrete high levels of neurotrophic factors (" NTFs "), modulate neuroinflammatory and neurodegenerative disease processes, promote neuron survival and improve neurological function.

Company Financials

EPS

BCLI has released its 2024 Q4 earnings. EPS was reported at -0.49, versus the expected -0.27, missing expectations. The chart below visualizes how BCLI has performed over recent quarters, highlighting trends in earnings surprises.